DiaSorin is pleased to announce the US launch of the FDA-Cleared LIAISON® Calprotectin test for the quantitative measurement of Calprotectin in stool samples. Following the recently announced strategic collaboration with Meridian Bioscience to sell Helicobacter pylori stool antigen test, DiaSorin continues to expand its Gastro-Intestinal portfolio in the United States
DiaSorin and QIAGEN® N.V. today announced the launch in the CE market of the LIAISON® QuantiFERON®-TB Gold Plus as an aid to detect latent tuberculosis infection (LTBI) on LIAISON® analyzer systems. The new test was developed in a partnership between DiaSorin and QIAGEN®.
DiaSorin receives clearance from the CE Notified Body to market the LIAISON® XL Murex Anti-HDV assay for the diagnosis of Hepatitis D virus (HDV) infection enlarging its CLIA menu for hepatitis on LIAISON® platforms.
DiaSorin is pleased to announce the launch of the new LIAISON® test for the measurement of SHBG (Sex Hormone-Binding Globulin) in human serum and plasma, available worldwide with the exception of the U.S. SGHB, which is produced in the liver, is involved in transport of sex steroids, such as dihydrotestosterone, testosterone and estradiol, in the blood stream. The combined measurement of SHBG and testosterone levels helps determining causes of infertility, decreased libido and erectile dysfunction in men, and diagnosing polycystic ovarian syndrome (PCOS) in women.
The 3 main renal biomarkers (FGF 23, 1,25 vit D, 1-84 PTH) in full automation to support the clinical outcome
WEDNESDAY JUNE 14 - EDUW 36
17.00 - 18.00 - MITROPULOS HALL
DiaSorin launches the new LIAISON® XL Zika Capture IgM, the first and the only fully automated test for specific and accurate diagnosis of Zika virus infection, following the Emergency Use Authorization (EUA) obtained in the United States over the past few weeks.